Semax raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-01-15 and is reviewed periodically as new material appears.
Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.
Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.
Lyophilised powder is normally kept at -20 °C in a desiccated container, with some suppliers recommending -80 °C for long-term archival storage. Repeated freeze-thaw cycles are the most common cause of avoidable loss, so aliquoting before freezing reduces variability between working sessions. Dissolved peptide is far less stable than the dry solid and is usually prepared fresh or held briefly at 4 °C. Aqueous solutions support both hydrolysis of the backbone and oxidation of the N-terminal methionine, and these two routes dominate degradation under ordinary laboratory conditions.
Identity and purity are confirmed with reversed-phase high-performance liquid chromatography, typically monitored at 214 nanometres where the peptide bond absorbs. Mass spectrometry, either electrospray or MALDI-TOF, verifies molecular mass against the theoretical value and detects truncation or adduct formation. Amino acid analysis and peptide mapping provide additional confirmation when required. The most frequently reported impurities are deletion sequences from incomplete coupling, methionine sulfoxide from oxidation, and dimeric species formed through non-covalent aggregation. Impurity profiles depend strongly on the synthesis and purification route chosen by the producer.
Published research has focused mainly on neurological and cognitive endpoints in animal models, with proposed mechanisms involving brain-derived neurotrophic factor and related signalling pathways. A substantial share of the human data originates from a limited number of research groups, and independent replication in other countries remains sparse. Regulatory status reflects that distribution: the peptide is registered as a medicine in Russia and appears in some neighbouring markets, while elsewhere it is handled as a research chemical without approved therapeutic labelling. Questions about dose-response relationships, long-term effects, and comparability across studies are still open.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic heptapeptide | Analog of an ACTH fragment |
| Amino acid length | Seven residues | Met-Glu-His-Phe-Pro-Gly-Pro |
| Origin | Moscow, 1980s | Institute of Molecular Genetics |
| Approved regions | Russia and some neighboring states | Not cleared in Western markets |
| Common trade names | Multiple national brands | Sold as a nasal formulation |
Clinical evidence consists largely of small trials with modest sample sizes, often without independent replication. Reported endpoints include cognitive scores, recovery after stroke, and visual function, but study designs vary widely and few trials meet contemporary reporting standards. Systematic reviewers have noted a high risk of bias in several of these reports. No large multicenter trial conducted outside Russia has been published. The compound is therefore best described as investigational in most jurisdictions, with its clinical role still unresolved.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its chain combines the first seven residues of corticotropin with a C-terminal proline-glycine-proline extension, a modification intended to slow enzymatic breakdown. The free peptide has a molecular mass near 813.9 daltons. It belongs to the class of ACTH-derived fragments studied for central nervous system activity rather than for adrenal steroid stimulation. This structural relationship to a natural hormone fragment is the usual starting point for describing the compound in the literature.
Development took place during the 1980s at institutes of the Russian Academy of Sciences, where peptide fragments of ACTH were screened for cognitive and neuroprotective effects. The compound received regulatory approval in Russia as a nasal preparation, marketed for conditions such as ischemic stroke, transient ischemic attacks, and optic nerve disorders. Registration in other countries has not followed. Most published clinical reports originate from a small number of Russian research groups, and independent replication outside that setting remains limited. The regulatory status therefore differs sharply between Russia and the rest of the world.
The peptide is prone to several degradation pathways. Oxidation of the methionine residue produces a sulfoxide that elutes close to the parent peak in many chromatographic systems. Hydrolysis of peptide bonds and deamidation of susceptible residues in related sequences also reduce purity over time. Lyophilised material kept dry at minus twenty degrees Celsius and shielded from light is the most stable form commonly described in laboratory practice.
Material sold for laboratory use varies widely in stated purity and documentation. A certificate of analysis should list the analytical method, the column and detector used, and the observed purity value. Independent verification by an outside laboratory is the practical way to confirm identity when documentation is absent or internally inconsistent. Regulatory status differs by country, and a product legal in one jurisdiction may be unapproved or controlled in another.
Gunman Chronicles is a 2000 first-person shooter game originally created as a mod by the now-defunct Rewolf Software. It was originally a Quake deathmatch mod named Gunmanship 101, then it was moved to Quake II's engine before becoming a Half-Life mod. Gunman Chronicles was popular at the Half-Life Mod Expo in 1999, and Sierra approached Rewolf to make a retail version. After significant work, it was released as a standalone game. Plans were drawn to release Gunman Chronicles on GameCube, but it was never released.
=== Phenol–chloroform extraction === Phenol-Chloroform extraction is a liquid-liquid method used by biochemists to separate nucleic acids from proteins and lipids after cells have been lysed. This method has fallen out of favor with scientists and microbiologists as there are easier methods available which require less hazardous chemicals.
Moreover, the PP opted for a greater alignment with the United States, which was immediately reflected in European policy, especially when in 2003 the debate on the draft European Constitution was opened, to which the Spanish government opposed by not accepting the distribution of votes proposed for the adoption of decisions in the European Councils. This policy of "international reaffirmation" was also reflected in the deterioration of relations with Morocco, which reached a peak of tension in the summer of 2002 on the occasion of the occupation by Moroccan gendarmes of the uninhabited Perejil Island, close to Ceuta, and which Spain considered under its sovereignty. Aznar's government decidedly supported the "war against terrorism" declared by President George W. Bush after the September 11 attacks in New York and Washington, so that when the United States started the Afghanistan war in October 2001 and the Iraq War in March 2003, it had his support despite the fact that in the second case the public opinion was mostly against it. Thus, four days after the beginning of the invasion of Iraq, the government decided to send a "joint humanitarian support unit", which arrived in Iraq one day after the fall of Baghdad, on April 9. Meanwhile, demonstrations against the war continued to take place ─ some led by the Socialist leader Rodríguez Zapatero.
Sources: en.wikipedia.org
it is believed to be the first prosecution of its kind. Dorset Police announce that no criminal offences were committed in relation to the 2023 Bournemouth beach incident in which two people were killed. 17 July – NHS consultants in England announce a further two days of strike action, on 24 and 25 August. 20 July – Parliamentary by-elections take place in Somerton and Frome, Uxbridge and South Ruislip, and Selby and Ainsty. 21 July – 21 July – July 2023 by-elections: Uxbridge and South Ruislip: The former seat of ex-PM Boris Johnson is held by the Conservatives, but with a reduced majority of 495 votes. Steve Tuckwell becomes the constituency's MP. The proposed ULEZ expansion by Labour's Sadiq Khan, Mayor of London, is a factor in the result. Selby and Ainsty: Labour takes the formerly safe Conservative seat of Selby and Ainsty. The swing of 23.7% is the largest since 1945. Keir Mather becomes the constituency's new MP, and at 25, the youngest Member of Parliament and Baby of the House. Somerton and Frome: The Liberal Democrats take Somerton and Frome, overturning a Conservative majority of 29.6%. Sarah Dyke is elected as the constituency's new MP. Planned strikes on the London Underground from 23 to 28 July are called off following last minute talks between union representatives and Transport for London. The Association of School and College Leaders, which represents headteachers in England, votes to accept 6.5% pay rise.
In his (August 1962) Report to the National Research Council of the National Academy of Sciences (AP.2), Archie Palmer reported that, of the 945 US "higher education institutions" he had surveyed, 349 had either "formulated and adopted a formalized research and patent policy", or were observing "a generally accepted practice with respect to the handling of research and patent matters", whilst the remaining 596 (which, he observed, conducted "little or no scientific or technological research") had "no formalized research or patent policies". In 1965, 96 US patents were granted to 28 "US universities or related institutions"; in 1992, 1500 US patents were granted to more than 150 "US universities or related institutions" (RH.2, p. 119). In 2025, the (formerly reluctant) University of California had been granted 571 patents, making the university's total "over 6,800 active patents" (JB.1). According to the economists Stanley Engerman and Gavin Wright (SE.1), (a) until 1933 there were more US patents issued to individuals than those issued to corporations, (b) by 1950 the ratio was 50:50, (c) by 1998, whilst the number of US patents issued to individual inventors remained more or less the same, (i.e., 10,000–15,000 per annum), they only represented approx. 10% of the number of patents issued.
However, no consistent correlation has been found between the degree of cognitive impairment and the severity of the sleep disturbance or hypoxia. These impairments may improve with an effective treatment for OSA, such as continuous positive airway pressure (CPAP) therapy. Driving a motor vehicle is an example of a complex task that relies on driver's cognitive abilities, such as attention, reaction time and vigilance. Very brief moments of inattention called microsleep events could be an indicator for daytime vigilance impairment. These may not be present in all drivers with obstructive sleep apnea.
Sources: en.wikipedia.org
A distinctive abnormality in skeletal muscle fibres on the cellular level; observable via light microscope Symptoms of muscle weakness and hypotonia Is a congenital disorder, meaning it occurs during development and symptoms present themselves at birth or in early life. Is a genetic disorder.
First, the Citizens Rights Directive 2004 article 4 says every citizen has the right to depart a member state with a valid passport. This has historical importance for central and eastern Europe, when the Soviet Union and the Berlin Wall denied its citizens the freedom to leave. Article 5 gives every citizen a right of entry, subject to national border controls. Schengen Area countries (not the UK and Ireland) abolished the need to show documents, and police searches at borders, altogether. These reflect the general principle of free movement in TFEU article 21. Second, article 6 allows every citizen to stay three months in another member state, whether economically active or not. Article 7 allows stays over three months with evidence of "sufficient resources... not to become a burden on the social assistance system". Articles 16 and 17 give a right to permanent residence after 5 years without conditions. Third, TEU article 10(3) requires the right to vote in the local constituencies for the European Parliament wherever a citizen lives.
== Interactions with other treatments == Since the kidney is also an important excretory organ for numerous drugs, chronic kidney disease must be taken into account in the drug therapy of other diseases. For example, the plasma half-life may be significantly prolonged (e.g. with numerous antibiotics) and the dose must be reduced accordingly. Drugs that can only be administered with caution in cats with kidney disease include atenolol, carbimazole, chlorothiazide, digoxin and thiamazole.
=== Phase 2 === ASP-8062 – GABAB receptor positive allosteric modulator – alcoholism BP-1.3656B (BP-1.3656; BP1.3656B; BP13656) – histamine H3 receptor antagonist – alcoholism BP-1.4979 (BP-1.4979; BP-14979; BP14979) – dopamine D3 receptor partial agonist – smoking withdrawal Brenipatide (LY-3537031) – glucagon-like peptide-1 (GLP-1) receptor agonist, gastric inhibitory polypeptide (GIP) receptor agonist – smoking withdrawal Buprenorphine sublingual ethanol-free (CHF-6563; CHF6563) – μ-opioid receptor agonist, δ-opioid receptor agonist, κ-opioid receptor antagonist, nociceptin receptor agonist – opioid-related disorders Buprenorphine/naloxone (naloxone/buprenorphine) – combination of buprenorphine (non-selective opioid receptor modulator) and naloxone (orally/sublingually inactive opioid receptor antagonist) – opioid-related disorders Bupropion/dextromethorphan (bupropion/DXM; Auvelity; AXS-05) – combination of bupropion (norepinephrine–dopamine reuptake inhibitor (NDRI), nicotinic acetylcholine receptor antagonist, CYP2D6 inhibitor) and dextromethorphan (DXM) (NMDA receptor antagonist, serotonin reuptake inhibitor, sigma receptor agonist, other actions) – smoking withdrawal Bupropion/naltrexone (Contrave; CX-101; Mysimba; naltrexone/bupropion; NB32) – combination of bupropion (norepinephrine–dopamine reuptake inhibitor (NDRI), nicotinic acetylcholine receptor antagonist) and naltrexone (opioid receptor antagonist) – smoking withdrawal Cannabidiol (CBD; A-1002-N5S; Nantheia) – cannabinoid/various actions – opioid-related disorders, smoking withdrawal Cannabidiol (CBD; Epidiolex; Epidyolex; Epidiolexa; GW-42003; GWP-42003; GWP-42003-P; JZP-926) – cannabinoid/various actions – heroin-related disorders, opioid-related disorders Centanafadine (CTN-SR; EB-1020) – serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) – smoking withdrawal Cocaine esterase (RBP-8000; TNX-1300) – enzyme replacement – cocaine-related disorders Cyproheptadine/prazosin (KT-110; Periactine/Alpress) – combination of cyproheptadine (various actions) and prazosin (α1-adrenergic receptor antagonist) – alcoholism Devextinetug (anti-methamphetamine chimeric monoclonal antibody; Ch-mAb7F9; IXT-m200; METH-mAb) – immunomodulator (monocloncal antibody against methamphetamine) – substance-related disorders F-652 (IL-22 IgG2 Fusion Protein; IL-22 IgG2-Fc; rhIL-22 dimer) – interleukin, immunoglobulin Fc fragment, recombinant fusion protein, anti-inflammatory, hepatoprotectant – alcoholism and alcoholic hepatitis Ibudilast (AV-411; Eyevinal; Ibinal; KC-404; Ketas; MN-166; Pinatos) – phosphodiesterase PDE4 inhibitor, toll-like receptor 4 (TLR4) antagonist – alcoholism, opioid-related disorders, substance-related disorders Liraglutide (LATIN-T1D; NN-2211; NN-9211; NN-8022; NNC-90-1170; Saxenda; Victoza) – glucagon-like peptide-1 (GLP-1) receptor agonist – smoking withdrawal Lixosicone (AEF-0117; AEF0117) – biased cannabinoid CB1 receptor negative allosteric modulator (pregnenolone derivative) – substance-related disorders Mavoglurant (AFQ-056; STP-7) – metabotropic glutamate mGlu5 receptor antagonist – alcoholism Mazdutide (IBI-362; LY-3305677; OXM-3) – glucagon-like peptide-1 (GLP-1) receptor agonist, glucagon receptor agonist – alcoholism Mebufotenin benzoate (5-MeO-DMT; BPL-002; BPL-003) – non-selective serotonin receptor agonist, serotonin 5-HT1A and 5-HT2A receptor agonist, serotonergic psychedelic – alcoholism Metyrapone/oxazepam (EMB-001C; EMB-001) – combination of metyrapone (11β-hydroxylase inhibitor and cortisol synthesis inhibitor) and oxazepam (benzodiazepine/GABAA receptor positive allosteric modulator) – cocaine-related disorders Midomafetamine (MDMA) – serotonin–norepinephrine–dopamine releasing agent (SNDRA), serotonin 5-HT2 receptor agonist, entactogen – alcoholism Mifepristone (C-1073; Corlux; Corluxin; Korlym; Mifegyne; Mifeprex; RU-38486; RU-486) – glucocorticoid, progesterone, and androgen receptor antagonist – alcoholism Miricorilant (CORT-118335) – glucocorticoid and mineralocorticoid receptor antagonist – alcoholism Nadolol (INV-102; INV102) – non-selective beta blocker (β1- and β2 adrenergic receptor agonist) – smoking withdrawal Neboglamine (nebostinel; CR-2249; XY-2401) – ionotropic glutamate glycine-gated NMDA receptor agonist – cocaine-related disorders NNC0194-0499 (NN-9500; NN-9499; NNC-0194-0499) – fibroblast growth factor (FGF) receptor agonist – substance-related disorders NS-2359 (GSK-372475) – serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) – cocaine-related disorders OMS-405 (OMS405) – PPARγ agonist – opioid-related disorders, smoking withdrawal Pemvidutide (ALT-801- Altimmune; SP-1373; VPD-107) – glucagon-like peptide-1 (GLP-1) receptor agonists, glucagon receptor agonist – alcoholism Psilocybin (SYNP-101; synthetic psilocybin) – non-selective serotonin receptor agonist, serotonin 5-HT2A receptor agonist, and serotonergic psychedelic – alcoholism Selonabant (ANEB-001; V-24343) – cannabinoid CB1 receptor antagonist – substance-related disorders Sunobinop (IMB-115; IT-1315; RSC117957; S-117957; V-117957) – nociceptin receptor agonist – alcoholism TA-CD (TA-CD; TA-CD09) – immunostimulant (cocaine vaccine) – cocaine-related disorders Zabaglurant (Heptares 25; HTL-0014242; HTL14242; TMP-301) – metabotropic glutamate mGlu5 receptor negative allosteric modulator – alcoholism Zolunicant (18-methoxycoronaridine; 18-MC; MM-110) – α3β4 nicotinic acetylcholine receptor antagonist – opioid-related disorders
Sources: en.wikipedia.org
It originated at the Institute of Molecular Genetics in Moscow during the 1980s. The work was carried out by a Russian research group that specialized in peptide neuropharmacology.
It is registered as a medicine in Russia and has been used clinically there for decades. No regulatory agency in Western Europe or North America has approved it for any indication.
Semax corresponds to the four-to-ten fragment of adrenocorticotropic hormone. Because it omits the first three residues, it lacks the adrenal-stimulating action of the full hormone.
Reversed-phase HPLC gives the main purity figure, most often with UV detection near 214 nanometres. Mass spectrometry then confirms the molecular mass. Together the two methods distinguish a correct sequence from a closely related impurity.